The cutting-edge OncoPortal™ Mutation Tracker add-on module enables precision monitoring of evolving genomic cancer drivers
BOSTON, MA and ROLLE, Switzerland, Jan. 28, 2025 /PRNewswire/ — SOPHiA GENETICS, a leading cloud-native healthcare technology company, has unveiled the OncoPortal™ Mutation Tracker. This advanced tool is designed to enhance disease monitoring in oncology by tracking genomic variants over time. This innovation underscores SOPHiA GENETICS’ commitment to leveraging data-driven approaches to improve healthcare outcomes.
A New Frontier in Cancer Monitoring
Effective cancer management increasingly relies on the precise detection of genetic mutations associated with the disease. The OncoPortal™ Mutation Tracker integrates longitudinal tracking capabilities with next-generation sequencing (NGS). This combined approach facilitates the detection of cancer-specific genetic mutations even at very low frequencies. By capturing these subtle genetic changes, clinicians gain a more accurate picture of disease progression and predict potential resistance to treatments.
Enhancing SOPHiA DDM™ Platform
The OncoPortal™ Mutation Tracker builds on the capabilities of the SOPHiA DDM™ Platform, enhancing its analytical core to support clinical researchers in monitoring evolving genomic variants. This comprehensive view of disease evolution allows for better stratification of patients and personalized treatment planning. The tool offers variable settings for low-frequency mutation selection, customizable thresholds, and reporting features, streamlining the process of genetic analysis.
Expert Insights
“The ability to reliably track low-frequency variants longitudinally is a game-changer because it allows the detection of even the smallest traces of cancer that can potentially escape traditional testing methods,” said Philippe Menu, M.D., Ph.D., Chief Medical Officer and Chief Product Officer of SOPHiA GENETICS. “This new capability offers a highly customizable, user-friendly solution that could lead to earlier interventions and improved disease management, contributing to better long-term outcomes for patients.”
“This interface represents the solution we’ve been searching for to fully integrate NGS into our oncology practice,” added Dr. Christophe Marzac, Head of the Hematology-Immunology Unit at Gustave Roussy Institute. “It opens a new frontier in personalized medicine by enabling detailed genetic tracking.”
Benefits for Oncology
The OncoPortal™ Mutation Tracker provides several key benefits in the field of oncology. By detecting residual disease or emerging variants early, it supports the management of Measurable Residual Disease (MRD). This capability is crucial for identifying treatment resistance and devising tailored therapies. Ultimately, it enhances the precision of cancer treatment, leading to better patient outcomes.
Exploring the OncoPortal™ Mutation Tracker
For more detailed information about the OncoPortal™ Mutation Tracker, visit SOPHiAGENETICS.com. Here, you can explore how this innovative tracking tool can be integrated into clinical practices, supporting meticulous disease monitoring and management.
About SOPHiA GENETICS
SOPHiA GENETICS is a pioneering cloud-native healthcare technology company dedicated to transforming patient care globally. Through its SOPHiA DDM™ Platform, it analyzes complex genomic and multimodal data to provide real-time, actionable insights for hospitals, laboratories, and biopharma institutions worldwide.
For more information, visit SOPHiAGENETICS.com and connect with the company on LinkedIn.
SOPHiA GENETICS products are exclusively for research use and may require approval for diagnostic use in different regions. For region-specific information, please contact @sophiagenetics.com.
Forward-Looking Statements
This press release includes forward-looking statements reflecting management’s beliefs and current expectations regarding future operations, products, and technology. These statements are subject to risks and uncertainties that may cause actual results to differ materially. SOPHiA GENETICS does not undertake any obligation to update such statements.
SOURCE SOPHiA GENETICS
Join the conversation by leaving a comment below, or subscribe to our newsletter for the latest updates in healthcare technology. Share this article on social media to help spread the word about this groundbreaking tool in oncology.